{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-013668","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.119549+00:00","generated_at":"2026-06-06T02:38:11.406847+00:00","sec_items":["1.01","2.03","3.02","3.03","5.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity Therapeutics issues $440K convertible note to 3i, LP; amends Series A conversion price to $0.405","bullets":["Second closing of $440K principal senior convertible note purchased for $400K (10% original issue discount), due February 2025.","Note carries 8% annual interest, convertible at $0.405 per share; Purchaser limited to 4.99% beneficial ownership cap.","Limited Waiver Agreement permits second closing before the 30-day waiting period required by the original purchase agreement.","Conversion price of Series A Preferred Stock amended from $0.4476 to $0.405 via Sixth Certificate of Amendment filed with Delaware.","Net proceeds to be used for accounts payable and working capital; negative covenants restrict additional indebtedness over $250K."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-013668","json":"https://secwatch.observer/filing/0001213900-24-013668.json","markdown":"https://secwatch.observer/filing/0001213900-24-013668.md","text":"https://secwatch.observer/filing/0001213900-24-013668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/ea193650-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:38:11.406847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93fd9ccf2b0774042a717e7670b3cab99d3e47f7","claim":"Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing 2025-02-13.","evidence_excerpt":"we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on February 13, 2025","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$440,000"},{"label":"Counterparty","value":"3i, LP"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"2025-02-13"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"6777c0f7db7c31a634decb82f284fb03ca1ddf9a","claim":"Allarity Therapeutics, Inc.: Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, we filed the Sixth Amendment to change the “Conversion Price” from $0.4476 to $0.405.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"governance_change"},{"claim_id":"ff4735be549060d2645e20de96f4c5268fa6c480","claim":"Allarity Therapeutics, Inc. entered into Limited Waiver Agreement and Second Convertible Promissory Note with 3i, LP valued at $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024 (the “Second Closing”), the Parties entered into a Limited Waiver Agreement (the “Waiver Agreement”) and agreed that the Second Closing can be consummated prior to the 30 th calendar day following January 18, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"3i, LP"},{"label":"Value","value":"$440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}